Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 1,726 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,726 shares of Twist Bioscience stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $71,939.68. Following the sale, the chief executive officer now directly owns 660,966 shares of the company’s stock, valued at $27,549,062.88. This represents a 0.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Twist Bioscience Stock Up 4.8 %

NASDAQ TWST opened at $44.94 on Tuesday. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The business has a fifty day moving average price of $45.42 and a two-hundred day moving average price of $45.31. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The stock has a market capitalization of $2.68 billion, a PE ratio of -13.30 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience’s revenue was up 24.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.75) earnings per share. Equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience during the third quarter worth $34,000. Van ECK Associates Corp grew its position in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares during the last quarter. Banque Transatlantique SA acquired a new position in Twist Bioscience in the 4th quarter worth about $43,000. GF Fund Management CO. LTD. bought a new position in Twist Bioscience in the fourth quarter valued at about $58,000. Finally, US Bancorp DE boosted its stake in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares in the last quarter.

Analysts Set New Price Targets

TWST has been the subject of several analyst reports. TD Cowen reiterated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a report on Tuesday, February 4th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird raised their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Finally, Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.